XORTX Therapeutics Inc. (XRTX)

USD 1.12

(-4.27%)

Market Cap (In USD)

3.89 Million

Revenue (In USD)

-

Net Income (In USD)

-2.85 Million

Avg. Volume

2.91 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.09-7.0
PE
-
EPS
-
Beta Value
-0.207
ISIN
CA98420Q3061
CUSIP
98420Q207
CIK
1729214
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Allen Warren Davidoff Ph.D.
Employee Count
-
Website
https://www.xortx.com
Ipo Date
2021-09-23
Details
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.